Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Alnylam Pharmaceuticals, Inc. (ALNY)

223.45   0.32 (0.14%) 08-19 00:45
Open: 223.97 Pre. Close: 223.13
High: 224.85 Low: 221
Volume: 462,772 Market Cap: 26,820(M)
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 227.13 - 228.98 228.98 - 230.22
Low: 218.39 - 220.44 220.44 - 221.81
Close: 220.46 - 223.62 223.62 - 225.74

Technical analysis

as of: 2022-08-18 3:50:42 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 276.58     One year: 323.04
Support: Support1: 174.17    Support2: 135.46
Resistance: Resistance1: 236.8    Resistance2: 276.58
Pivot: 208.95
Moving Average: MA(5): 228.04     MA(20): 192.21
MA(100): 152.78     MA(250): 164.82
MACD: MACD(12,26): 22.1     Signal(9): 20.3
Stochastic oscillator: %K(14,3): 88.3     %D(3): 91.1
RSI: RSI(14): 70
52-week: High: 236.8  Low: 117.58
Average Vol(K): 3-Month: 980 (K)  10-Days: 907 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ALNY ] has closed below upper band by 39.0%. Bollinger Bands are 280.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.

Headline News

Thu, 18 Aug 2022
Alnylam discovery of genetic mutations could lead to therapies for diabetes, obesity - Seeking Alpha

Thu, 18 Aug 2022
2022-08-18 | NDAQ:ALNY | Press Release | Alnylam Pharmaceuticals Inc. - Stockhouse

Thu, 18 Aug 2022
Alnylam to Present Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the 18th International Symposium on Amyloidosis - Yahoo Finance

Wed, 17 Aug 2022
Commonwealth Equity Services LLC Sells 193 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World

Thu, 11 Aug 2022
Alnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $252.00 - Defense World

Sun, 07 Aug 2022
Tolga Tanguler Sells 1841 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock - Defense World

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 120 (M)
Shares Float 239 (M)
% Held by Insiders 0.5 (%)
% Held by Institutions 99.2 (%)
Shares Short 4,990 (K)
Shares Short P.Month 4,740 (K)

Stock Financials

EPS -7.49
EPS Est Next Qtl -1.37
EPS Est This Year -5.2
EPS Est Next Year -5.33
Book Value (p.s.) 1.46
Profit Margin (%) -111
Operating Margin (%) -80.9
Return on Assets (ttm) -13.1
Return on Equity (ttm) -190.6
Qtrly Rev. Growth 1.8
Gross Profit (p.s.) 5.86
Sales Per Share 7.36
EBITDA (p.s.) -5.6
Qtrly Earnings Growth 0
Operating Cash Flow -578 (M)
Levered Free Cash Flow 158 (M)

Stock Valuations

PE Ratio -29.92
PEG Ratio -3.7
Price to Book value 153.47
Price to Sales 30.41
Price to Cash Flow -46.52

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.